结合PSA密度、PI-RADS评分与定性描述特征界定多参数MRI上不确定(Likert 3/5分)前列腺外周带病灶
回顾性纳入330例前瞻性接受3T多参数MRI(无直肠内线圈)后行20区经会阴模板前列腺穿刺活检的患者,筛选出外周带最高Likert评分3/5分者。PSAD在显著癌组与非显著癌/无癌组间差异有统计学意义(p=0.004),而PSA无差异(p=0.915);主观Likert评估区分显著癌优于PI-RADS_v2。
要点
- PSAD在显著癌组(中位0.19 ng ml-2)与非显著癌/无癌组(中位0.13 ng ml-2)间差异有统计学意义。
- PSA在两组间差异无统计学意义(p=0.915)。
- 主观Likert评估区分显著癌优于PI-RADS_v2,读者间一致率分别为83%与56%。
核心结论
- PSAD可能有助于对Likert 3/5分外周带多参数MRI患者中显著癌的存在进行归类;作者认为PSAD可用于不确定外周带多参数MRI,以指导活检与监测之间的决策。
研究设计与样本
- 回顾性选取自330例前瞻性接受3T多参数MRI(无直肠内线圈)并随后行20区经会阴模板前列腺穿刺活检+/-局灶靶向活检的患者;PSA与PSAD分析纳入76例,PI-RADS评分分析纳入71例,形态学评估纳入67例(排除明显图像伪影)。
关键影像表现/征象
- 多参数MRI形态学特征在显著癌组与非显著癌/无癌组间差异无统计学意义。
诊断标准与关键数值
- 显著癌定义为≥Gleason 3+4,非显著癌/无癌定义为≤Gleason 3+3或无癌。
- PSAD在显著癌组中位0.19 ng ml-2(四分位距0.13-0.29),在非显著癌/无癌组中位0.13 ng ml-2(四分位距0.10-0.17),组间p=0.004。
- PSA在两组间p=0.915。
- 主观Likert评估的读者间百分比一致率为83%,PI-RADS_v2为56%。
临床应用与阅片要点
- 对Likert评分3/5分的外周带多参数MRI不确定病灶,可结合PSAD(而非单独PSA)辅助区分显著癌与非显著癌/无癌。
- 作者认为PSAD可用于不确定外周带多参数MRI,以指导活检与监测之间的决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features.
METHODS: Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies +/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 + 4) or insignificant cancer (≤ Gleason 3 + 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann-Whitney test and morphological descriptors with Fisher's exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated.
RESULTS: 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml-2 (interquartile range: 0.13-0.29)] and non-significant/no cancer [median: 0.13 ng ml-2 (interquartile range: 0.10-0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2.
CONCLUSION: PSAD may categorize presence of significant cancer in patients with Likert-scored 3/5 PZ mpMRI findings. Advances in knowledge: PSAD may be used in indeterminate PZ mpMRI to guide decisions between biopsy vs monitoring.
引用
- Brizmohun Appayya M, Sidhu HS, Dikaios N, et al. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. Br J Radiol. 2017. PMID: 29189042. doi:10.1259/bjr.20170645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。